Altimmune, Inc. (3G0.F)
| Previous close | 6.43 |
| Open | 6.32 |
| Bid | 6.31 x 440000 |
| Ask | 6.49 x 420000 |
| Day's range | 6.32 - 6.32 |
| 52-week range | 1.97 - 13.70 |
| Volume | |
| Avg. volume | 367 |
| Market cap | 447.818M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.44 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 20 Jan 2017 |
| 1y target est | 30.86 |
PR NewswireRoundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)
Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs.
Simply Wall St.Altimmune First Quarter 2024 Earnings: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)
Altimmune ( NASDAQ:ALT ) First Quarter 2024 Results Key Financial Results Net loss: US$24.4m (loss widened by 22% from...
GlobeNewswireAltimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2
